



Summary of Investigation Results

Ampicillin sodium, ampicillin sodium/cloxacillin sodium hydrate, ampicillin hydrate, ampicillin hydrate/cloxacillin sodium hydrate, bacampicillin hydrochloride, sultamicillin tosilate hydrate

September 18, 2018

Non-proprietary name

- a. Ampicillin sodium
- b. Ampicillin sodium/cloxacillin sodium hydrate
- c. Ampicillin hydrate
- d. Ampicillin hydrate/cloxacillin sodium hydrate
- e. Bacampicillin hydrochloride
- f. Sultamicillin tosilate hydrate

Branded name (Marketing authorization holder)

- a. Viccillin 0.25g for injection, Viccillin 0.5g for injection, Viccillin 1g for injection, Viccillin 2g for injection (Meiji Seika Pharma Co., Ltd.)
- b. Viccillin-S100 for Injection, Viccillin-S500 for Injection, Viccillin-S1000 for Injection (Meiji Seika Pharma Co., Ltd.)
- c. Viccillin Capsules 250 mg, Viccillin Dry Syrup 10% (Meiji Seika Pharma Co., Ltd.)
- d. Viccillin-S Combination Tablets (Meiji Seika Pharma Co., Ltd.)
- e. Pengood Tablets 250 mg (Nichi-Iko Pharmaceutical Co., Ltd.)



- f. Unasyn Tablets 375 mg, Unasyn Fine Granules for Pediatric Use 10% (Pfizer Japan Inc.)

Indications

See Attachment

Summary of revisions

a.-d.

“Acute generalized exanthematous pustulosis” should be added to the language concerning toxic epidermal necrolysis and oculomucocutaneous syndrome in the Clinically Significant Adverse Reactions section.

e.

“Acute generalized exanthematous pustulosis” should be added to the language concerning oculomucocutaneous syndrome and toxic epidermal necrolysis in the Clinically Significant Adverse Reactions section.

f.

“Acute generalized exanthematous pustulosis” should be added to the language concerning toxic epidermal necrolysis, oculomucocutaneous syndrome, and exfoliative dermatitis in the Clinically Significant Adverse Reactions section.

Investigation results and background of the revision

Cases of acute generalized exanthematous pustulosis have been reported in patients treated with preparations containing ampicillin sodium or ampicillin hydrate, or with bacampicillin hydrochloride in Japan. Considering the fact that bacampicillin hydrochloride and sultamicillin tosilate hydrate are prodrugs of ampicillin, MHLW/PMDA concluded that revision of the package insert was necessary based on the results of their investigation of the currently available evidence and in consultation with expert advisors.



Number of adverse reactions and patient mortalities reported in Japan during the previous 3 fiscal years

a.

A total of 2 cases involving acute generalized exanthematous pustulosis have been reported to date (a causal relationship with the product could not be ruled out for these cases.) No patient mortalities have been reported to date.

b.-f.

No cases involving acute generalized exanthematous pustulosis have been reported to date.



This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Attachment

Brand name (Marketing authorization holder)	Launched in Japan	Indications
a. Viccillin 0.25g for injection, Viccillin 0.5g for injection Viccillin 1g for injection, Viccillin 2g for injection (Meiji Seika Pharma Co., Ltd.)	October 2009	<Relevant microorganisms> Ampicillin-susceptible strains of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> , <i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Neisseria gonorrhoeae</i> , <i>Neisseria meningitidis</i> , <i>Bacillus anthrax</i> , <i>Actinomyces</i> , <i>Escherichia coli</i> , <i>Shigella</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> , <i>Listeria monocytogenes</i> <Relevant conditions> Sepsis, infective endocarditis, Superficial skin infections, deep-seated skin infections, lymphangitis/lymphadenitis, chronic pyoderma, secondary infections following trauma, thermal burn, and surgical wound, mastitis, osteomyelitis, pharyngitis/laryngitis, tonsillitis, acute bronchitis, pneumonia, lung abscess, pyothorax, secondary infections of chronic respiratory lesions, cystitis, pyelonephritis, gonococcal infection, peritonitis, liver abscess, infectious enteritis, intrauterine infection, pyogenic meningitis, abscess of eyelid, keratitis (including corneal ulcer), otitis media, sinusitis, periodontal inflammation, pericoronitis, jaw inflammation, secondary infections following tooth extraction wound and oral surgery wound, scarlet fever, anthrax, actinomycosis
b. Viccillin-S100 for Injection (Meiji Seika Pharma)	October 2009	1. Bacterial infection prophylaxis 2. Others <Relevant microorganisms>



This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Co., Ltd.)		Ampicillin/cloxacillin-susceptible strain of of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> , <i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Escherichia coli</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> <Relevant conditions> Chronic pyoderma, pharyngitis/laryngitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory lesions, otitis externa
b. Vicillin-S500 for Injection, Vicillin-S1000 for Injection (Meiji Seika Pharma Co., Ltd.)	August 1970 (S500) September 1976 (S1000)	<Relevant microorganisms> Ampicillin/cloxacillin-susceptible strain of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> , <i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Escherichia coli</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> <Relevant conditions> Sepsis, pneumonia, lung abscess, secondary infections of chronic respiratory lesions, cystitis, pyelonephritis
c. Vicillin Capsules 250 mg (Meiji Seika Pharma Co., Ltd.)	September 2009	<Relevant microorganisms> Ampicillin hydrate-susceptible strain of of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> , <i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Neisseria gonorrhoeae</i> , <i>Bacillus anthrax</i> , <i>Actinomycete</i> , <i>Escherichia coli</i> , <i>Shigella</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> , <i>Treponema pallidum</i> <Relevant conditions> Superficial skin infections, deep-seated skin infections, lymphangitis/lymphadenitis, chronic pyoderma, secondary infections following trauma, thermal burn, and surgical wound, mastitis, osteomyelitis, pharyngitis/laryngitis, tonsillitis, acute bronchitis, pneumonia, lung abscess, pyothrax, secondary infections of chronic respiratory lesions, cystitis, pyelonephritis, gonococcal infection,



This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

		syphilis, peritonitis, liver abscess, infectious enteritis, intrauterine infection, abscess of eyelid, hordeolum, keratitis (including corneal ulcer), otitis media, sinusitis, periodontal inflammation, pericoronitis, jaw inflammation, secondary infections following tooth extraction wound and oral surgery wound, scarlet fever, anthrax, actinomycosis
c. Vicillin Dry Syrup 10% (Meiji Seika Pharma Co., Ltd.)	October 2009	<Relevant microorganisms> Ampicillin hydrate-susceptible strain of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> , <i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Neisseria gonorrhoeae</i> , <i>Bacillus anthrax</i> , <i>Actinomycete</i> , <i>Escherichia coli</i> , <i>Shigella</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> <Relevant conditions> Superficial skin infections, deep-seated skin infections, lymphangitis/lymphadenitis, chronic pyoderma, secondary infections following trauma, thermal burn, and surgical wound, mastitis, osteomyelitis, pharyngitis/laryngitis, tonsillitis, acute bronchitis, pneumonia, lung abscess, pyothorax, secondary infections of chronic respiratory lesions, cystitis, pyelonephritis, gonococcal infection, peritonitis, liver abscess, infectious enteritis, intrauterine infection, abscess of eyelid, hordeolum, keratitis (including corneal ulcer), otitis media, sinusitis, periodontal inflammation, pericoronitis, jaw inflammation, secondary infections following tooth extraction wound and oral surgery wound, scarlet fever, anthrax, actinomycosis
d. Vicillin-S Combination Tablets (Meiji	September 2009	<Relevant microorganisms> Ampicillin/cloxacillin-susceptible strain of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> ,



This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Seika Pharma Co., Ltd.)		<i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Escherichia coli</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> <Relevant conditions> Pneumonia, lung abscess, secondary infections of chronic respiratory lesions
e. Pengood Tablets 250 mg (Nichi-Iko Pharmaceutical Co., Ltd.)	November 2001	<Relevant microorganisms> Ampicillin-susceptible strain of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> , <i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Neisseria gonorrhoeae</i> , <i>Escherichia coli</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> <Applicable conditions> Superficial skin infections, deep-seated skin infections, lymphangitis/lymphadenitis, chronic pyoderma, secondary infections following trauma, thermal burn, and surgical wound, mastitis, pharyngitis/laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory lesions, cystitis, pyelonephritis, gonococcal infection, peritonitis, intrauterine infection, uterine adnexitis, abscess of eyelid, hordeolum, keratitis (including corneal ulcer), otitis media, sinusitis, periodontal inflammation, pericoronitis, secondary infections following tooth extraction wound and oral surgery wound, scarlet fever
f. Unasyn Tablets 375 mg, (Pfizer Japan Inc.)	October 2009	<Relevant microorganisms> Sulbactam/ampicillin-susceptible strain of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> , <i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Neisseria gonorrhoeae</i> , <i>Escherichia coli</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> <Applicable conditions>



This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

			Superficial skin infections, deep-seated skin infections, lymphangitis/lymphadenitis, chronic pyoderma, pharyngitis/laryngitis, tonsillitis, acute bronchitis, pneumonia, lung abscess, secondary infections of chronic respiratory lesions, cystitis, pyelonephritis, gonococcal infection, intrauterine infection, dacryocystitis, keratitis (including corneal ulcer), otitis media, sinusitis
f. Unasyn Fine Granules for Pediatric Use 10% (Pfizer Japan Inc.)	December 2009		<Relevant microorganisms> Sulbactam/ampicillin-susceptible strain of genus <i>Staphylococcus</i> , genus <i>Streptococcus</i> , <i>Pneumococcus</i> , genus <i>Enterococcus</i> , <i>Escherichia coli</i> , <i>Proteus mirabilis</i> , <i>Haemophilus influenzae</i> <Applicable conditions> Superficial skin infections, deep-seated skin infections, lymphangitis/lymphadenitis, chronic pyoderma, pharyngitis/laryngitis, tonsillitis, acute bronchitis, pneumonia, lung abscess, secondary infections of chronic respiratory lesions, cystitis, pyelonephritis, otitis media, sinusitis